SCHEMBL24796132

SCHEMBL24796132

C[C@@H]1C(=O)N(CCNC(=O)CSCC(=O)O)C(=O)[C@H]1C

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ HIF1A Q16665 1/20 0.35
▸ FABP4 P15090 2/20 0.34
▸ FABP3 P05413 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24796127 1.00 GAA (0.38) GAAUSP2L3MBTL1ALDH1A1CYP2D6
SCHEMBL21383928 1.00 GAA (0.38) GAAUSP2L3MBTL1ALDH1A1CYP2D6
SCHEMBL24796115 1.00 GAA (0.38) GAAUSP2L3MBTL1ALDH1A1CYP2D6
SCHEMBL26746701 0.88 KMT2A (0.33) USP2ALDH1A1TP53MAPTSMN1; SMN2
SCHEMBL24796301 0.88 HSD17B10 (0.35) USP2ALDH1A1TP53POLBMAPT
SCHEMBL21389158 0.87 USP2 (0.39) GAAUSP2L3MBTL1ALDH1A1FABP4
SCHEMBL24795885 0.87 USP2 (0.39) GAAUSP2L3MBTL1ALDH1A1FABP4
SCHEMBL21389252 0.87 GAA (0.33) GAAUSP2L3MBTL1ALDH1A1FABP4
SCHEMBL21389177 0.85 GAA (0.36) GAAUSP2L3MBTL1ALDH1A1CYP2D6
SCHEMBL21389394 0.84 GAA (0.38) GAAUSP2L3MBTL1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 — — US disclosed
US-11535660-B1 Modulators of G-protein coupled receptors Cannot Therapeutics, Inc. (US) 2022-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR GAA 1526/4885USP2 2595/4885L3MBTL1 2127/4885
US-11535660-B1 Modulators of G-protein coupled receptors GIPR, GLP1R, GCGR GAA 1536/4885USP2 2718/4885L3MBTL1 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback